USANA HEALTH SCIENCES, INC. Deferred Tax Assets, Unrealized Currency Losses
USANA HEALTH SCIENCES, INC. (USNA) had Deferred Tax Assets, Unrealized Currency Losses of $1.71 million as of 2026-01-03, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses · last filed 2026-03-16
- 2026-01-03: Deferred Tax Assets, Unrealized Currency Losses $1.71M.
- 2024-12-28: Deferred Tax Assets, Unrealized Currency Losses $2.07M.
- 2023-12-30: Deferred Tax Assets, Unrealized Currency Losses $1.76M.
- 2022-12-31: Deferred Tax Assets, Unrealized Currency Losses $1.45M.
| Period end | Deferred Tax Assets, Unrealized Currency Losses | Deferred Tax Assets, Unrealized Currency Losses as first filed |
|---|---|---|
| 2026-01-03 | $1.71M 10-K · filed 2026-03-16 | |
| 2024-12-28 | $2.07M 10-K · filed 2026-03-16 | |
| 2023-12-30 | $1.76M 10-K · filed 2025-03-12 | |
| 2022-12-31 | $1.45M 10-K · filed 2024-02-27 | |
| 2022-01-01 | $0.00 10-K · filed 2023-02-28 | $126.00K 10-K · filed 2022-03-01 |
| 2021-01-02 | $1.69M 10-K · filed 2022-03-01 | $0.00 10-K · filed 2021-03-02 |
| 2019-12-28 | $537.00K 10-K · filed 2021-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Niagen Bioscience, Inc. (NAGE) | United States | $0.238B | 15.72 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B | |
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Cronos Group Inc. (CRON) | $1.223B | ||
| Definium Therapeutics, Inc. (DFTX) | United States | $4.931B | -17.87 |